Citations

Clear

69 citation(s) found for "Feagan, Brian".

DOP82 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: Post hoc analysis of the phase 2b/3 SELECTION study
Feagan, Brian G. , Yun, Chohee , Hsieh, Jeremy, Liu, X, Zhao, Sally, Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Loftus, Edward V. , Vermeire, Séverine

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S112-S113

10.1093/ecco-jcc/jjab073.121 Get It

Abstract Background Filgotinib (FIL) is a once-daily, oral, preferential Janus kinase 1 inhibitor in development for the treatment of inflammatory bowel disease. FIL for the treatment of moderately to severely active ulcerative colitis (UC) was evaluated in the phase 2b/3 randomized, double-blind, placebo (PBO)-controlled SELECTION study (NCT02914522). Long-term use of corticosteroids (CS) is associated with significant side effects. The aim of this post hoc analysis was to assess the CS-sparing effects of FIL in the SELECTION study. Methods Patients (18–75 years old) with moderately to severely active UC were randomized (2:2:1) to receive FIL 100 mg (n = 564), FIL 200 mg (n = 507) or PBO (n = 280) once daily orally for up to 11 weeks (induction study). At week 11, FIL induction responders were rerandomized 2:1 to continue their induction FIL dose or to receive PBO (maintenance study). CS use was kept stable up to week 14, at which point mandatory CS tapering occurred. CS could be resumed during the maintenance study; however, if the baseline CS dose was exceeded this was considered treatment failure. In this post hoc analysis, CS-free remission was defined as remission at week 58 (endoscopic subscore ≤ 1, rectal bleeding subscore = 0 and ≥ 1-point decrease in stool frequency subscore to achieve 0 or 1) without systemic or localized CS use that was indicated for UC in the previous 1, 3, 6 or 8 months. Results The baseline characteristics of patients in the maintenance study were similar across treatment groups (Table 1). Of the 92 patients receiving CS at maintenance baseline (week 11; maintenance week 0) who received FIL 200 mg during the maintenance study, 25 (27%) were in remission at week 58 and had been continuously CS-free for at least the previous 6 months (Table 2). The proportion of CS-free remitters in the FIL 200 mg group was consistently higher than with PBO (Table 2). In patients taking CS at maintenance baseline who had continued CS-use post baseline, lower median prednisone dosing was observed with FIL 200 mg than with PBO throughout the maintenance study (maximum difference at week 34 [maintenance week 23]: 5.0 mg vs 13.8 mg) (Figure 1). In SELECTION, a total of 199 patients received FIL 200 mg in the maintenance study, of whom 74 (37.2%) were in remission at week 58; of these 74 patients, 69 (93.2%) were continuously CS-free for at least the previous 6 months (Figure 2). Conclusion In this post hoc analysis of SELECTION maintenance study data, FIL 200 mg was effective in reducing and eliminating CS use through to week 58 in patients with moderately to severely active UC. The vast majority of patients taking FIL 200 mg who were in remission at week 58 had not taken CS in the previous 6 months.
P383 Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION study
Hibi∥, Toshifumi , Birchwood, Christine, Yun, Chohee , Zhao, Sally, Liu, X, Colombel, J F, Feagan, Brian G. , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Rogler, Gerhard , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S395-S396

10.1093/ecco-jcc/jjab076.507 Get It

Abstract Background Filgotinib (FIL), an oral preferential Janus kinase 1 inhibitor, was evaluated for the treatment of ulcerative colitis in the phase 2b/3 double-blind, placebo (PBO)-controlled SELECTION study (NCT02914522). Clinical, histological and endoscopic remission rates at week 58 were significantly greater with FIL 200 mg than with PBO (p < 0.025 for all comparisons). Here, we identify disease characteristics contributing to histo-endoscopic mucosal healing (HEMH; Geboes histological remission and endoscopic subscore ≤ 1) at week 58. FIL 100 mg data are excluded from by-treatment summaries because histological and endoscopic remission rates were not significantly different from PBO in SELECTION. Methods Eligible patients (18–75 years old) with moderately to severely active ulcerative colitis were enrolled in Induction Study A (biologic-naïve) or B (biologic-experienced) and randomized to receive FIL 200 mg, FIL 100 mg or PBO (2:2:1) once daily for up to 11 weeks, with response assessed at week 10. At week 11, FIL responders were re-randomized 2:1 to continue their induction FIL dose or to receive PBO for the 47-week maintenance study. PBO responders continued receiving PBO. For the maintenance study, univariate logistic regression was used to identify baseline and week 10 disease characteristics associated with HEMH (defined as achieving both Geboes histological remission [Grade 0 of ≤0.3, Grade 1 of ≤ 1.1, Grade 2a of ≤ 2A.3, Grade 2b of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0] and an endoscopic subscore of 0 or 1) at week 58 for patients receiving FIL 200 mg; variables with p < 0.05 in the univariate analysis were included in a multivariate analysis. Results Patients had similar characteristics across the treatment groups for both the induction (Table 1) and maintenance studies (Table 2). HEMH was achieved in a greater proportion of patients receiving FIL 200 mg than those receiving respective PBO at week 58 (32.7% vs 10.2%; p < 0.0001). No associations between disease characteristics (at baseline and week 11) and HEMH at week 58 were found (Table 3). Conclusion FIL 200 mg was effective at establishing HEMH compared with PBO at week 58; there were no baseline characteristics identified to be associated with HEMH at week 58.
OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Bossuyt, Peter , Ferrante, Marc , Baert, Filip , Feagan, Brian G. , Ran, Zhi Hua , Armuzzi, Alessandro , D’Haens, Geert , Song, Alexandra , Neimark, Ezequiel, Liao, Xiaoli , Zhou, Qing , Wallace, Kori, Bossuyt, Peter , Danese, Silvio , Loftus, Edward V. , Panés, Julián , Peyrin‐Biroulet, Laurent , Berg, S, Panaccione, Remo

Mayo Clinic

Journal of Crohn's and Colitis | May 27, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S033-S034

10.1093/ecco-jcc/jjab075.035 Get It

Abstract Background Endoscopic healing has become a critical treatment target in Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin 23, is being investigated as a treatment for moderate-to-severe CD. This analysis assessed different endoscopic endpoints in patients treated with RZB induction therapy in two double-blind, randomised, placebo (PBO)-controlled studies (ADVANCE [NCT03104413] and MOTIVATE [NCT03105128]). Methods Patients with moderate-to-severe CD (CD Activity Index [CDAI] of 220–450, Simple Endoscopic Score for CD [SES-CD] ≥ 6 [≥ 4 for isolated ileal disease] excluding the narrowing component, and average daily [liquid/very soft] stool frequency [SF] ≥ 4 and/or average daily abdominal pain [AP] score ≥ 2) who had demonstrated prior inadequate response or intolerance to conventional and/or biologic treatment (ADVANCE) or to biologic treatment (MOTIVATE) were randomised 2:2:1 (ADVANCE) or 1:1:1 (MOTIVATE) to receive intravenous (IV) RZB 600 mg, RZB 1200 mg, or PBO at weeks 0, 4, and 8. This analysis evaluated the proportion of patients who achieved endoscopic remission ulcer-free endoscopy (ie, absence of ulcers), and composite endpoints of CDAI clinical response and endoscopic response, and enhanced clinical response and endoscopic response at week 12 (endpoints defined in Figure 1 footnotes). All endoscopies were centrally read by a blinded reviewer. Safety was assessed throughout the studies. Results In ADVANCE and MOTIVATE, 850 and 569 patients, respectively, were randomised and included in the intent-to-treat population for this analysis. At week 12 greater proportions of RZB- vs PBO-treated patients in both studies achieved endoscopic remission (P ≤ .001), ulcer-free endoscopy (P ≤ .01), CDAI clinical response and endoscopic response (P ≤ .001), and enhanced clinical response and endoscopic response (P ≤ .001; Figure 1). Treatment with RZB 600 mg or 1200 mg was well tolerated, and no new safety risks were identified.1,2 Conclusion Induction therapy with IV RZB 600 mg or 1200 mg resulted in improved outcomes at week 12 compared with PBO as assessed by endoscopy and by composite endoscopic-clinical endpoints in patients with moderate-to-severe CD. References
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease
Gordon, Ilyssa O. , Bokemeyer, Arne , Rosty, Christophe , Robert, Marie E. , Mao, Ren, Borralho, Paula , Pai, Reetesh K. , Odze, Robert D. , Feakins, Roger , Parker, Claire E. , Guizzetti, Leonardo , Nguyen, Tran M , Shackelton, Lisa M. , Sandborn, William J. , Baker, Mark E. , Bruining, David H. , Feagan, Brian G. , Pai, Rish K. , Rieder, Florian , Bettenworth, Dominik , Bokemeyer, Arne , Rosty, Christophe , Mao, Ren , Pai, Reetesh K , Bruining, David, Feagan, B G , Pai, R K , Rieder, Florian , Guizzetti, L , Gordon, Ilyssa O , Srivastava, Amitabh , Hertogh, Gert D. , Valasek, Mark A. , Li, Jiannan , Harpaz, Noam , Jairath, Vipul , Fletcher, Joel G.

Mayo Clinic

Gut | May 5, 2021 | Volume: 71 | Issue: 3 | Pages: 479-486

10.1136/gutjnl-2021-324374 | PMID 33952604 Get It

Objective Effective medical therapy and validated trial outcomes are lacking for small bowel Crohn’s disease (CD) strictures. Histopathology of surgically resected specimens is the gold standard for correlation with imaging techniques. However, no validated histopathological scoring systems are currently available for small bowel stricturing disease. We convened an expert panel to evaluate the appropriateness of histopathology scoring systems and items generated based on panel opinion. Design Modified RAND/University of California Los Angeles methodology was used to determine the appropriateness of 313 candidate items related to assessment of CD small bowel strictures. Results In this exercise, diagnosis of naïve and anastomotic strictures required increased bowel wall thickness, decreased luminal diameter or internal circumference, and fibrosis of the submucosa. Specific definitions for stricture features and technical sampling parameters were also identified. Histopathologically, a stricture was defined as increased thickness of all layers of the bowel wall, fibrosis of the submucosa and bowel wall, and muscularisation of the submucosa. Active mucosal inflammatory disease was defined as neutrophilic inflammation in the lamina propria and any crypt or intact surface epithelium, erosion, ulcer and fistula. Chronic mucosal inflammatory disease was defined as crypt architectural distortion and loss, pyloric gland metaplasia, Paneth cell hyperplasia, basal lymphoplasmacytosis, plasmacytosis and fibrosis, or prominent lymphoid aggregates at the mucosa/submucosa interface. None of the scoring systems used to assess CD strictures were considered appropriate for clinical trials. Conclusion Standardised assessment of gross pathology and histopathology of CD small bowel strictures will improve clinical trial efficiency and aid drug development.
S0662 Evaluating the Optimum Number of Biopsies to Assess Histologic Inflammation in Ulcerative Colitis
Pai, Rish K. , Wang, Zhongya , McDonald, John WD, Duijvestein, Marjolijn , Jeyarajah, Jenny , Parker, Claire E. , Viegen, Tanja van, Nelson, Sigrid, Boland, Brigid S. , Singh, Siddharth , Dulai, Parambir S. , Feagan, Brian G. , Sandborn, William J. , Battat, Robert , Casteele, Niels Vande , Zou, Guangyong , Valasek, Mark A. , Jairath, Vipul

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S331-S332

10.14309/01.ajg.0000704696.77507.99 Get It

Etrolizumab induction therapy improves patient-reported outcomes, endoscopic activity and histologic severity in patients with moderate-severe Ulcerative colitis after failure of anti-TNF therapy: results from the HICKORY open label induction trial
Rubin, DT, Feagan, Brian G. , Oh, YS, Tyrrell, Helen E.J., Pai, RK, Boruvka, Audrey, Scherl, Alexis , Williams, S., Tole, Swati, Thommes, James, Hasselblatt, Peter , Peyrin‐Biroulet, Laurent , Rubin, DT, Williams, S

Mayo Clinic

Zeitschrift für Gastroenterologie | September 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1716048 Get It

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Dulai, Parambir S. , Battat, Robert , Barsky, Maria, Nguyen, Nghia , Narula, Neeraj , Boland, Brigid S. , Murad, M. Hassan , D’Haens, Geert , Feagan, Brian G. , Sandborn, William J. , Singh, Siddharth , Murad, M Hassan , Ma, Christopher , Mosli, Mahmoud Hisham , Casteele, Niels Vande , Prokop, Larry J. , Jairath, Vipul

Mayo Clinic

American Journal of Gastroenterology | May 8, 2020 | Volume: 115 | Issue: 6 | Pages: 885-894

10.14309/ajg.0000000000000596 | PMID 32384283 Get It

INTRODUCTION: We applied the Grading of Recommendations, Assessment, Development, and Evaluation framework to evaluate the performance of fecal calprotectin (FC) as an alternative to endoscopy in patients with moderate-to-severe ulcerative colitis (UC) treated with a biologic agent or tofacitinib. METHODS: Individual participant data from the trials of infliximab, golimumab, vedolizumab, and tofacitinib for UC were pooled to generate prevalence of endoscopic activity (Mayo endoscopy score) across different combinations of the rectal bleeding score (RBS) and stool frequency score (SFS). These estimates were then combined with the data from an updated systematic review of the operating properties of FC to generate clinical scenario–specific assessments of the performance of FC as a predictor of endoscopic disease activity. A prespecified threshold of acceptability for false-negative (FN) and false-positive (FP) test results was set at 5%. RESULTS: For patients with UC achieving RBS 0 + SFS 0/1, FC ≤ 50 μg/g may avoid endoscopy in 50% patients with a FN rate <5%. Similarly, for patients with RBS 2/3 + SFS 2/3, FC ≥ 250 μg/g potentially avoids endoscopy in approximately 50% patients with an FP rate <5%. The greatest uncertainty in the diagnostic performance for FC was observed in patients with UC achieving RBS 0 but having SFS 2/3, where FN and FP rates were consistently >10%, and endoscopic evaluation may be warranted. DISCUSSION: Two clinical scenarios were identified where FC can be used with confidence for monitoring treatment response to biologics or tofacitinib in patients with UC without the requirement for endoscopy.
Editorial: histologic normalisation in ulcerative colitis
Pai, Rish K. , Jairath, Vipul , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 16, 2020 | Volume: 51 | Issue: 3 | Pages: 399-401

10.1111/apt.15617 | PMID 31943274 Get It

LINKED CONTENTThis article is linked to Cushing et al and Cushing and Ananthakrishnan papers. To view these articles, visit https://doi.org/10.1111/apt.15568 and https://doi.org/10.1111/apt.15621.
P069 Correlation Between Histologic Indices and Ulcerative Colitis Activity Measures Among Patients in the HICKORY (Etrolizumab) Open-Label Induction Cohort
Feagan, Brian, Pai, Rish K. , Boruvka, Audrey, Scherl, Alexis , Scalori, Astrid, Arrisi, Pablo, Tole, Swati, Peyrin‐Biroulet, Laurent , Oh, Young Suk , Rubin, David T.

Mayo Clinic

American Journal of Gastroenterology | December 3, 2019 | Volume: 114 | Issue: 1 | Pages: S18-S18

10.14309/01.ajg.0000613244.26833.fe Get It

BACKGROUND: Cross-sectional studies in ulcerative colitis (UC) have shown at best a moderate association between histologic and clinical measures of disease activity, but few longitudinal studies have evaluated this relationship. As endoscopy and histology are both independent predictors of clinical outcomes in UC, there remains a need to assess these measures in parallel to demonstrate clinical benefit. HICKORY (NCT02100696) is an ongoing Phase 3 study evaluating etrolizumab in anti-tumor necrosis factor (aTNF)–experienced patients with moderate-to-severe UC. The correlation between histologic changes and established disease activity measures at end of induction (week 14) was assessed using data from the open-label induction (OLI) cohort of HICKORY. METHODS: Study analysis is based on data from patients in the OLI cohort who received ≥1 dose of etrolizumab 105 mg subcutaneously every 4 weeks during the 14-week induction phase. Baseline and week 14 biopsies were scored by 1 of 4 central readers using the Nancy histologic index (NHI) and the Robarts histopathology index (RHI) in patients who had active baseline histology (NHI >1 and RHI >3) and complete scoring at week 14 (n = 97). Binary week 14 histologic outcomes were characterized by presence or absence of neutrophils (NHI ≤1 or RHI ≤3 and Geboes subgrades 2B.0/3.0). Mayo Clinic score (MCS) endoscopic subscore (ES) was used to assess endoscopy. Pairwise associations were quantified by Spearman correlation (ρ; for correlation between change from baseline scores) and Cohen kappa coefficients (κ; for agreement among week 14 outcomes). ΔNHI and ΔRHI were compared to determine presence of a minimum clinically important difference (MCID) in MCS (∆MCS ≥3 from baseline). RESULTS: At week 14, 22% (21/97), 23% (22/97), and 8% (8/97) of patients achieved resolution of neutrophilic inflammation based on either NHI or RHI/Geboes, endoscopic improvement (ES ≤ 1), and endoscopic remission (ES = 0), respectively. Among patients with endoscopic improvement and endoscopic remission, neutrophilic resolution was achieved in 55% (12/22) and 75% (6/8) of patients, respectively. ΔNHI and ΔRHI were highly correlated (ρ = 0.91). There was weak to no association between ΔNHI/ΔRHI/ΔES and Δfecal calprotectin (ρ = –0.02 to 0.38), ΔC-reactive protein (ρ = 0.03 to 0.07), Δalbumin (ρ = –0.19 to –0.10), Δhemoglobin (ρ = –0.22 to –0.19), and Δsegmented neutrophils in the blood (ρ = –0.06 to 0.01). Weak correlations were observed between ΔNHI/ΔRHI and ΔES (ρ = 0.26–0.27), Δrectal bleeding (ρ = 0.24–0.28), and Δstool frequency (ρ = 0.40–0.42). Correlations between NHI, RHI/Geboes, and ES with symptomatic outcomes were weak (κ = 0.28–0.45). Difference in the mean grouped by achievement of ΔMCS ≥3 suggests MCIDs in ΔNHI and ΔRHI of 1.2 and 8.6, respectively. CONCLUSION(S): The analysis showed weak to moderate agreement between changes in histologic scores and changes in endoscopic scores, and weak to no agreement between changes in histologic scores and changes in laboratory results at week 14. There was a weak correlation between histologic scores and symptoms at the end of induction. MCID results suggest that both the NHI and RHI appear to effectively evaluate neutrophilic resolution, making the changes in score more clinically interpretable.
Editorial: evolving histological assessment of NASH. Authors' reply
Pai, Rish K. , Feagan, Brian G. , Parker, Claire E. , Jairath, Vipul , Loomba, Rohit , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Loomba, Rohit , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | November 11, 2019 | Volume: 50 | Issue: 11-12 | Pages: 1245-1246

10.1111/apt.15570 | PMID 31709613 Get It

LINKED CONTENTThis article is linked to Pai et al and Rowe papers. To view these articles, visit https://doi.org/10.1111/apt.15503 and https://doi.org/10.1111/apt.15537.